// App-Quantinova.ai

: Phosphatidylserine Receptor Enhancement of SARS-CoV-2 Entry: AXL as a Therapeutic Target for COVID-19

Researchers

Presenter

  • Dana Bohan

Principal Investigators

  • Hanora Van Ert

  • Kai Rogers

  • Natalie Ruggio

  • Roberth Anthony Rojas Chávez

  • Tomasz Stokowy

  • Hillel Haim

  • Boning Gao

  • John Minna

  • David Micklem

  • James Lorens

  • Wendy Maury

Medical Centers

  • Department of Microbiology and Immunology, University of Nevada, Reno, NV

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • University of Bergen, Bergen, Norway

  • BerGenBio Ltd, United Kingdom

Locations

  • United States

  • Norway

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Coronavirus disease

Biomarkers

  • Stromal interaction molecule 1

Drug/Treatment

  • Phosphatidylserine

  • R428

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved